Pilot study evaluating the efficacy and toxicity of irinotecan plus oral etoposide for platinum- and taxane-resistant epithelial ovarian cancer
Pilot study evaluating the efficacy and toxicity of irinotecan plus oral etoposide for platinum- and taxane-resistant epithelial ovarian cancer
复制标题
DOI：
10.1016/j.ygyno.2007.03.036
复制
发表时间：
2007-08-01
影响因子：
4.7
通讯作者：
Kamura, Toshiharu
中科院分区：
文献类型：
--
作者：
Nishio, Shin;Sugiyama, Toru;Kamura, Toshiharu
目标。评价静脉注射伊立替康联合口服依托泊苷化疗对铂和紫杉烷耐药女性上皮性卵巢癌的疗效和毒性。在2002年10月至2005年9月期间，我们研究了27名患有铂和紫杉烷耐药上皮性卵巢癌的妇女。伊立替康在28天周期的第1天和第15天静脉注射剂量为70 mg/m(2)，每次输注90分钟，依托泊苷在第1至21天口服剂量为50 mg/天。对于重度预处理的患者，伊立替康的初始剂量降至60mg /m2。重复治疗周期直至疾病进展或出现不可接受的毒性。所有27例患者均符合条件并可评估。部分缓解11例，完全缓解1例，总缓解率44.4%。总体缓解和病情稳定的中位持续时间分别为11个月和8个月。主要毒性为中性粒细胞减少症（3级，22.2%；4级，37.1%）。腹泻少见且轻微，胃肠道毒性适中且可控。急性髓系白血病（M5）发展为继发性恶性肿瘤1例。我们的初步研究结果表明，伊立替康联合口服依托泊苷对铂和紫杉烷耐药的女性上皮性卵巢癌有效且耐受。(C) 2007爱思唯尔公司版权所有。
Objectives. To evaluate the efficacy and toxicity of combination chemotherapy with intravenous irinotecan and oral etoposide in women with platinum- and taxane-resistant epithelial ovarian cancer.Methods. Between October 2002 and September 2005, we studied 27 women with platinum- and taxane-resistant epithelial ovarian cancer. Irinotecan was administered in an intravenous dose of 70 mg/m(2) as a 90-min infusion on days 1 and 15 of a 28-day cycle, and etoposide was administered in an oral dose of 50 mg/day on days 1 to 21. For heavily pretreated patients, the initial dose of irinotecan was lowered to 60 mg/m2. Treatment cycles were repeated until disease progression or unacceptable toxicity.Results. All 27 patients were eligible and assessable. There were 11 partial responses and 1 complete response for an overall response rate of 44.4%. The median durations of overall response and of stable disease were 11 months and 8 months, respectively. The major toxicity was neutropenia (grade 3, 22.2%; grade 4, 37.1%). Diarrhea was infrequent and mild, and gastrointestinal toxicity was moderate and manageable. Acute myeloid leukemia (M5) developed as a secondary malignancy in 1 patient.Conclusions. The results of our pilot study suggest that a combination of irinotecan and oral etoposide is effective and tolerable in women with platinum- and taxane-resistant epithelial ovarian cancer. (C) 2007 Elsevier Inc. All rights reserved.